Company Overview

Silo Wellness Inc. is a wellness and psychedelics-focused company that has historically operated in the emerging functional mushroom, psychedelic wellness, and consumer packaged wellness sectors. The company has pursued business activities tied to psychedelic-assisted wellness experiences, psychedelic education, and consumer wellness products, with particular attention to jurisdictions where psychedelic-related activities are legally permitted. Public disclosures and market materials indicate that the company has explored opportunities involving psilocybin wellness retreats, ketamine-related wellness initiatives, and functional mushroom consumer products.

The company has positioned itself around early participation in the regulated psychedelic wellness market, especially through wellness retreat operations and intellectual property related to psychedelic experiences. Silo Wellness evolved from a broader wellness and cannabis-related operating model into a more focused psychedelics and wellness strategy as public interest and regulatory developments around psychedelic therapies accelerated in North America and certain international markets. Data regarding the scale of current commercial operations and long-term revenue concentration is limited in recent publicly available disclosures, and some operational details are inconclusive based on available public sources.

Business Operations

Silo Wellness has historically reported activities across wellness retreats, consumer wellness products, and psychedelic-related intellectual property initiatives. The company’s business model has included revenue opportunities from wellness retreats, branded products, licensing arrangements, and strategic partnerships tied to psychedelic wellness experiences. Public filings and investor communications indicate involvement with psilocybin wellness retreats in jurisdictions where such activities may be legally conducted, including operations connected to the Caribbean region.

The company has also referenced intellectual property development related to psychedelic formulations and wellness methodologies. Its operations have included partnerships with local operators and service providers supporting retreat experiences and wellness programming. Publicly available information indicates that Silo Wellness has maintained a relatively asset-light operational structure compared with larger pharmaceutical-focused psychedelic companies. Information regarding the materiality of subsidiaries, joint ventures, or long-term contracted partnerships remains limited, and certain operational relationships are not fully detailed in available public disclosures.

Strategic Position & Investments

Silo Wellness has pursued a strategy centered on participation in the early-stage psychedelic wellness industry rather than large-scale pharmaceutical drug development. The company has emphasized experiential wellness offerings, consumer accessibility, and brand positioning in legally permissive markets. Strategic initiatives discussed in public materials have included expansion of psychedelic wellness retreats, development of wellness-oriented intellectual property, and participation in public conversations surrounding psychedelic legalization and mental wellness innovation.

The company has also explored opportunities connected to ketamine wellness and functional mushroom products as adjacent growth categories within the broader alternative wellness sector. Public disclosures indicate that management has sought to position Silo Wellness within emerging regulatory frameworks governing psychedelic-assisted wellness. Compared with larger competitors focused on clinical-stage therapeutics, Silo Wellness has generally appeared to emphasize consumer-facing wellness experiences and market entry flexibility. Information regarding major acquisitions or large-scale institutional investments is limited in publicly available records.

Geographic Footprint

Silo Wellness is headquartered in Canada and has pursued operations and partnerships in both North America and parts of the Caribbean. Public filings and company materials have highlighted activity in jurisdictions where psychedelic retreat experiences may be legally facilitated, particularly in Jamaica. The company’s strategic focus on Jamaica has been linked to the country’s legal environment surrounding psilocybin-containing mushrooms.

The company’s broader market visibility has also extended into the United States and Canada, particularly through investor relations activity and wellness-related product positioning. While Silo Wellness has referenced international expansion opportunities, publicly verifiable information regarding extensive operational infrastructure outside these regions remains limited. Data concerning large-scale international assets or significant foreign subsidiaries is inconclusive based on available public sources.

Leadership & Governance

Silo Wellness has been led by executives with backgrounds spanning wellness entrepreneurship, public markets, and emerging psychedelic industries. Public company disclosures indicate that leadership has focused on positioning the business around regulatory-compliant psychedelic wellness opportunities and early-stage market development. Governance practices are subject to public company reporting obligations associated with its listing status and applicable securities regulations.

Key executives and leadership figures identified in public disclosures have included:

• Douglas K. Gordon – Chief Executive Officer
• Mike Arnold – Founder and Executive Chairman

Public materials have emphasized entrepreneurial leadership, early-mover positioning within psychedelic wellness markets, and a strategy oriented toward experiential wellness offerings rather than conventional pharmaceutical commercialization. Certain executive and governance details may vary across reporting periods, and some historical leadership information is inconclusive based on available public sources.